噻氯匹定的血液学毒性？（作者译）
[Hematological toxicity of ticlopidine? (author's transl)].
作者信息
de Gramont A, Canuel C, Krulik M, Bauters F, Degos L, Marty M, Najean Y
出版信息
Nouv Rev Fr Hematol (1978). 1982;24(1):35-7.
PMID:7071010
Abstract
Four cases of bone marrow aplasia, with temporary agranulocytosis (one of them fatal) are described in patients treated with Ticlopidine, an anti-aggregating drug prescribed for prevention of thromboembolic disease. These data suggest that a systematic hematological assessment would be required in the first three months after initiation of Ticlopidine therapy.
摘要
本文描述了4例使用噻氯匹定治疗的骨髓再生障碍伴暂时性粒细胞缺乏症（其中1例死亡）的病例，噻氯匹定是一种用于预防血栓栓塞性疾病的抗血小板聚集药物。这些数据表明，在开始噻氯匹定治疗后的前三个月需要进行系统的血液学评估。
Zotero 插件